.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DD01_Cefotaxime.Cefotaxime

Information

Cefotaxime is a third-generation cephalosporin antibiotic used for the treatment of serious bacterial infections, including those caused by susceptible Gram-negative and some Gram-positive bacteria. It is approved and widely used in clinical practice, especially for severe infections such as sepsis, pneumonia, urinary tract infections, and meningitis.

Pharmacokinetics

Pharmacokinetic parameters reported from studies in healthy adult subjects; single dose intravenous administration.

References

1. Hartman, SJF, et al., & de Wildt, SN (2022). Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children. The Journal of antimicrobial chemotherapy 77(6) 1725–1732. DOI:10.1093/jac/dkac095 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35383374

2. Maksoud, E, et al., & Jacqz-Aigrain, E (2018). Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease. Antimicrobial agents and chemotherapy 62(4) –. DOI:10.1128/AAC.00637-17 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29378711

3. Sullins, AK, & Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatric drugs 15(2) 93–117. DOI:10.1007/s40272-013-0017-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23529866

Revisions

• 06/2025 initial generated model